Paysign (NASDAQ:PAYS – Free Report) had its target price raised by Ladenburg Thalmann & Co. Inc. from $14.00 to $15.25 in a report released on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.
Other analysts have also issued research reports about the stock. Barrington Research set a $15.00 target price on shares of Paysign in a research note on Tuesday, August 11th. DA Davidson lowered their target price on shares of Paysign from $15.00 to $14.00 and set a “buy” rating for the company in a report on Wednesday. Maxim Group lowered shares of Paysign from a “buy” rating to a “hold” rating in a research report on Wednesday. Lake Street Capital boosted their price target on shares of Paysign from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday, September 15th. Finally, Weiss Ratings raised shares of Paysign from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 8th. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $14.81.
Get Our Latest Analysis on Paysign
Paysign Stock Up 0.3%
Paysign (NASDAQ:PAYS – Get Free Report) last posted its earnings results on Monday, November 9th. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. Paysign had a return on equity of 35.29% and a net margin of 18.48%. The company had revenue of $30.80 million for the quarter, compared to analyst estimates of $29.02 million. As a group, research analysts anticipate that Paysign will post 0.62 EPS for the current year.
Insider Transactions at Paysign
In other Paysign news, EVP Joan M. Herman sold 38,900 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $11.74, for a total value of $456,686.00. Following the sale, the executive vice president owned 609,421 shares of the company’s stock, valued at $7,154,602.54. This trade represents a 6.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Michael C. Ngo sold 79,925 shares of Paysign stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $12.74, for a total value of $1,018,244.50. Following the sale, the insider owned 2,350,000 shares of the company’s stock, valued at approximately $29,939,000. This trade represents a 3.29% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 259,904 shares of company stock valued at $3,402,424. 24.50% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Paysign
Institutional investors and hedge funds have recently bought and sold shares of the stock. Caxton Associates LLP purchased a new position in Paysign in the 3rd quarter worth approximately $257,000. HighTower Advisors LLC bought a new position in shares of Paysign in the 3rd quarter worth $297,000. Virtus Advisers LLC purchased a new stake in shares of Paysign during the 3rd quarter valued at $282,000. Diversified Trust Co purchased a new stake in shares of Paysign during the 3rd quarter valued at $234,000. Finally, Russell Investments Group Ltd. raised its position in shares of Paysign by 171.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 156,825 shares of the company’s stock valued at $2,114,000 after buying an additional 98,980 shares in the last quarter. 25.89% of the stock is owned by hedge funds and other institutional investors.
About Paysign
Paysign, Inc. provides prepaid card programs, payment processing and related financial technology services. Its platform supports organizations that need to distribute funds and manage payments, including businesses in the healthcare sector. The company serves plasma collection centers with donor compensation and payment solutions, and works with pharmaceutical companies on patient assistance and affordability programs. Its services also support payments for clinical trials and other disbursement needs.
Featured Articles
- Five stocks we like better than Paysign
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Paysign Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paysign and related companies with MarketBeat.com's FREE daily email newsletter.
